Biblio

Author Title Type [ Year(Desc)]
Filters: Author is Oh, Sung Yong  [Clear All Filters]
2015
Shin H-J, Yoon DHyun, Lee HSup, Oh SYong, Yang DHwan, Kang HJin, Chong SYoung, Park Y, Do YR, Lim S-N, et al. Induction chemotherapy followed by up-front autologous stem cell transplantation may have a survival benefit in high-risk diffuse large B cell lymphoma patients. Exp Hematol. 2015.
2022
Kim KHa, Lee JHoon, Lee M, Kim H-G, Do YRok, Park Y, Oh SYong, Shin H-J, Kim WSeog, Park S-K, et al. Busulfan, Melphalan, and Etoposide (Bume) Showed an Equivalent Effect to Busulfan, Cyclophosphamide, and Etoposide (BuCE) as Conditioning Therapy for Autologous Stem Cell Transplantation in Patients with Relapsed or High Risk Non-Hodgkin's Lymphoma: A Mul. Cancer Res Treat. 2022.
Yi JHo, Jeong SHyun, Kim SJin, Yoon DHyun, Kang HJin, Koh Y, Kim JSeok, Lee W-S, Yang D-H, Do YRok, et al. Outcomes in Refractory Diffuse Large B-Cell Lymphoma: Results from Two Prospective Korean Cohorts. Cancer Res Treat. 2022.
2023
Kim SJin, Jo J-C, Yoon DHyun, Yang D-H, Yoon SEun, Lee G-W, Kong JHyun, Park Y, Kang K-W, Lee H-S, et al. Comparison of first-line treatment with CHOP versus ICED in patients with peripheral T-cell lymphoma eligible for upfront autologous stem cell transplantation. Front Oncol. 2023;13:1230629.
Kim DJung, Jeong S, Kong SGim, Lee S, Lim S-N, Oh SYong, Do YRok, Lee WSik, Lee MHong, Bae SHwa, et al. Incidence and risk factors of opportunistic infections after autologous stem cell transplantation: a nationwide, population-based cohort study in Korea. Sci Rep. 2023;13(1):2551.